Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Could patients with iridociliary body cyst receive posterior phakic intraocular lens implantation for high myopia correction?

Search Title by author or title

Session Details

Session Title: Phakic IOLs

Session Date/Time: Monday 09/10/2017 | 08:30-10:20

Paper Time: 09:49

Venue: Meeting Center Room I

First Author: : X.Wang CHINA

Co Author(s): :    X. Zhang   X. Zhou                 

Abstract Details

Purpose:

To investigate the clinical characters and effect of iridociliary body cysts among patients who had undergone posterior phakic intraocular lens implantation.

Setting:

Eye & ENT hospital of Fudan University

Methods:

A total 1569 eyes of 866 high myopia patients who underwent phakic intraocular lens implantation from 1 September 2010 to 31 August 2015. Intervention: iridociliary body cysts. Main Outcome Measures: Uncorrected visual acuity (UCVA), refraction, best corrected visual acuity (BCVA), ultrasound biomicroscopy (UBM), intraocular pressure (IOP), vault and adverse events.

Results:

218 eyes (14%) of 154 patients were diagnosed with iridociliary body cysts by ultrasound biomicroscopy.After 1 week postoperative follow-up, there were no significant differences in clinical outcomes between the cysts group and no cysts group, but the proportion of 20/20 or better UCVA, BCVA, and the2 types of vector astigmatism. IOP, refraction, and vault remained stable at different time points of the follow-up period, while vault of cysts patients tend to be lower than patients without cysts at more than 12 months.

Conclusions:

Iridociliary body cysts were more common than estimated and it had no impact on Phakic Intraocular Lens implantation because there was no clue to show significantly difference on postoperative clinical outcomes between the patients with and without iridociliary body cysts in this study.

Financial Disclosure:

NONE

Back to previous